What You Should Know:
– Clinical trials technology company Medidata has acquired the digital biomarker business of MC10.
– MC10’s offerings will bring novel clinical analytics and biosensor capabilities to Medidata’s existing technology solutions, enhancing Medidata’s capabilities to integrate data from wearable sensors – including clinical grade metrics – in clinical trials.
– With this acquisition, Medidata’s integrated offering will help provide life sciences companies and device developers with greater understanding of diseases, transformational therapies, and novel endpoints.
Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions to support the entire clinical development process, acquired the digital biomarker business of MC10. MC10’s offerings will bring novel clinical analytics and biosensor capabilities to Medidata’s existing Patient Cloud solutions in ePRO (patient-reported outcomes), eCOA (clinical outcome assessments), and biomarker discovery. This will enhance Medidata’s capabilities of integrating data from wearable sensors – including clinical grade metrics – to help customers successfully virtualize clinical trials.
MC10 Background
MC10 is a Lexington, MA-based privately held company focused on improving human health through digital solutions. The company combines conformal BioStamp sensors with clinical analytics to unlock novel insights from physiological data collected from the home or in clinical settings. The company flagship product, BioStamp nPoint, is intended for the clinical research community.
Why It Matters
Remote, patient-centered technologies have become an essential part of clinical research, especially in the age of COVID-19; the physical restrictions placed on patients and clinical sites caused by the pandemic can interfere with launching a clinical study and carrying it to completion. Wearable sensors are used in about 15 percent of studies, and the use of sensors is expected to grow to approximately 70 percent by 2025.*
Medidata leads the industry in building and integrating new technologies to revolutionize clinical research in pursuit of patient-centric therapy development. MC10’s focus on clinical-grade data capture and novel digital biomarker development represents an important next chapter – advancing the understanding of disease progression and treatment effect in the home.
“Medidata is excited to add the pioneering work at MC10 to our ongoing efforts in building a new platform for ingestion and analytics across a wide array of mobile sensors,” said Anthony Costello, senior vice president, Mobile Health, Medidata. “Incorporating remote biometric data capture and analysis that includes the MC10 nPoint Biostamp, alongside other leading mobile devices, will further strengthen the Medidata platform and help propel the digital transformation of life sciences.”
Acquisition Builds Integrated Offering
An integrated Medidata offering will provide research companies and device developers new and innovative ways to collect, normalize, and analyze data in pursuit of new therapy development. This enhanced capability will also create a closer connection between patients and the ecosystem of trailblazing researchers, practitioners, and life science companies committed to deepening a shared understanding of the disease, transformational therapies, and novel endpoints.
“Medidata is an exceptional fit for MC10. Our combined expertise will help customers and partners take a more data-driven approach to bringing targeted therapies to patients,” said Ben Schlatka, co-founder and CEO, MC10. “We are looking forward to moving ahead together, accelerating the development and deployment of new innovative offerings for our customers and ultimately transforming therapy development to improve the lives of patients.”
